Alan B. Sandler

9.8k citations

109 papers · 7.5k indexed · 2 hit papers · h-index 44

Oncology top 0.5%
Pulmonary and Respiratory Medicine top 0.5%
Molecular Biology top 5%
Cancer Research top 2%
Immunology top 5%

Co-authors: Joan H. Schiller David H. Johnson Julie R. Brahmer Janessa Laskin Roy S. Herbst Herbert I. Hurwitz David Miles Regula Deurloo
Topics: Lung Cancer Treatments and Mutations (70 papers)Lung Cancer Research Studies (40 papers)Lung Cancer Diagnosis and Treatment (24 papers)
Cited by: Oncology Pulmonary and Respiratory Medicine Cancer Research
Journals: New England Journal of Medicine Journal of Clinical Oncology Cancer
Partner nations: United States Canada United Kingdom

In The Last Decade

Alan B. Sandler

106 papers receiving 7.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

2020 780 citations Alan B. Sandler et al. profile →
Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer

2000 606 citations Alan B. Sandler, Joachim von Pawel et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Alan B. Sandler

Since Specialization

Citations

This map shows the geographic impact of Alan B. Sandler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan B. Sandler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan B. Sandler more than expected).

Fields of papers citing papers by Alan B. Sandler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan B. Sandler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan B. Sandler. The network helps show where Alan B. Sandler may publish in the future.

Co-authorship network of co-authors of Alan B. Sandler

This figure shows the co-authorship network connecting the top 25 collaborators of Alan B. Sandler. A scholar is included among the top collaborators of Alan B. Sandler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan B. Sandler. Alan B. Sandler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1323MO ASPEN-03: A randomized phase II study of evorpacept in combination with pembrolizumab in patients with recurrent, unresectable or metastatic (R/M) PD-L1 positive head and neck squamous cell carcinoma (HNSCC) 2025 ·Annals of Oncology ·Bhumsuk Keam,(unknown),J-P. Machiels,Sjoukje F. Oosting,(unknown),(unknown),Alison Forgie,Daniel Brickman,Athanasios C. Tsiatis,Alan B. Sandler,(unknown)	0
2	1324MO ASPEN-04: A randomized phase II study of evorpacept in combination with pembrolizumab and chemotherapy in patients with recurrent, unresectable or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) 2025 ·Annals of Oncology ·(unknown),Ming Hong,Beatriz Cirauqui,J-P. Machiels,Sjoukje F. Oosting,SH Lee,Annette M. Lim,(unknown),Alison Forgie,Daniel Brickman,Athanasios C. Tsiatis,Alan B. Sandler,Bhumsuk Keam	0
3	Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab 2012 ·Lung Cancer ·Heather A. Wakelee,Suzanne E. Dahlberg,Julie R. Brahmer,Joan H. Schiller,Michael C. Perry,Corey J. Langer,Alan B. Sandler,Chandra P. Belani,David H. Johnson	26
4	Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer 2012 ·Clinical Lung Cancer ·Giorgio V. Scagliotti,Silvia Novello,Joan H. Schiller,Vera Hirsh,Lecia V. Sequist,Jean‐Charles Soria,Joachim von Pawel,Brian Schwartz,Reinhard von Roemeling,Alan B. Sandler	112
5	Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab 2012 ·Journal of Thoracic Oncology ·Tien Hoang,Suzanne E. Dahlberg,Alan B. Sandler,Julie R. Brahmer,Joan H. Schiller,David H. Johnson	49
6	Angiogenesis in the Treatment of Non-Small Cell Lung Cancer 2009 ·Proceedings of the American Thoracic Society ·Leora Horn,Alan B. Sandler	28
7	Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study 2008 ·Clinical Cancer Research ·Afshin Dowlati,Robert J. Gray,Alan B. Sandler,Joan H. Schiller,David H. Johnson	208
8	Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer 2008 ·Journal of Thoracic Oncology ·Mary O’Brien,Mark A. Socinski,(unknown),Igor Bondarenko,Antoaneta Tomova,(unknown),Yevhen Hotko,(unknown),(unknown),Amy J. Eisenfeld,Larissa Sandalic,F. B. Oldham,B. Bandstra,Alan B. Sandler,Jack W. Singer	96
9	Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599 2007 ·Journal of Clinical Oncology ·Suresh S. Ramalingam,Suzanne E. Dahlberg,Corey J. Langer,Robert J. Gray,Chandra P. Belani,Julie R. Brahmer,Alan B. Sandler,Joan H. Schiller,David H. Johnson	251
10	P1-052: Menopausal status of women may affect survival in advanced NSCLC: Analysis of recent Eastern Cooperate Oncology Group (ECOG) studies using age of 60 years or older as a surrogate marker 2007 ·Journal of Thoracic Oncology ·Heather A. Wakelee,Suzanne E. Dahlberg,Joan H. Schiller,Corey J. Langer,Alan B. Sandler,Julie R. Brahmer,Chandra P. Belani,David H. Johnson	5
11	Inhibition of angiogenesis in the treatment of non‐small cell lung cancer 2007 ·Cancer Science ·Vicki L. Keedy,Alan B. Sandler	49
12	Systemic Therapy of Bronchioloalveolar Carcinoma: Results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma 2006 ·Journal of Thoracic Oncology ·Mark G. Kris,Giuseppe Giaccone,Angela M. Davies,Masahiro Fukuoka,David Garfield,Jacek Jassem,Élisabeth Quoix,Alan B. Sandler,Giorgio V. Scagliotti,Jan P. van Meerbeeck,Howard West	20
13	Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors 2005 ·Cancer Chemotherapy and Pharmacology ·Hiroyuki Kobayashi,S. Gail Eckhardt,Jennifer A. Lockridge,Mace L. Rothenberg,Alan B. Sandler,Cindy L. O’Bryant,Wendy Cooper,Scott N. Holden,Roger Aitchison,Nassim Usman,(unknown),M. Basche	28
14	Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Therapy 2004 ·Seminars in Respiratory and Critical Care Medicine ·Janessa Laskin,Alan B. Sandler	9
15	Chemotherapy for small cell lung cancer 2003 ·Seminars in Oncology ·Alan B. Sandler	92
16	Phase I Trial of Topotecan Plus Vinorelbine With/Without Filgrastim (G-CSF) in Patients With Refractory Malignancies 2002 ·American Journal of Clinical Oncology ·Nasser H. Hanna,Michael S. Gordon,Karen Fife,Alan B. Sandler	1
17	A Phase I Study of Weekly Gemcitabine and Docetaxel in Patients with Advanced Cancer: A Hoosier Oncology Group Study 2002 ·Oncology ·Kristen N. Ganjoo,Michael S. Gordon,Alan B. Sandler,(unknown),Karen Fife,(unknown),R. Seshadri,Patrick J. Loehrer	11
18	Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer:a Hoosier Oncology Group randomized study 2002 ·Annals of Oncology ·Nasser H. Hanna,Alan B. Sandler,Patrick J. Loehrer,Rafat Ansari,Sung‐Ho Jung,Kathleen A. Lane,Lawrence H. Einhorn	51
19	The Epidemiology of Lung Cancer 2001 ·Cancer treatment and research ·Mark D. Williams,Alan B. Sandler	91
20	Irinotecan (CPT-11) in Triplet Combinations in Patients with Advanced Non–Small-Cell Lung Cancer: A Review and Report of a Phase I/II Trial 2001 ·Clinical Lung Cancer ·Mark A. Socinski,Alan B. Sandler,Langdon L. Miller,Paula K. Locker,(unknown),Gary Elfring,Valerie K. Israel,Nicoletta Pirotta,Ronald B. Natale	3

About Alan B. Sandler

Alan B. Sandler is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology, having authored 109 papers that have together received 7.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (70 papers), Lung Cancer Research Studies (40 papers) and Lung Cancer Diagnosis and Treatment (24 papers). The work is most often cited by research in Oncology (4.5k citations), Pulmonary and Respiratory Medicine (3.7k citations) and Cancer Research (1.0k citations). Alan B. Sandler has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Joan H. Schiller, David H. Johnson, Julie R. Brahmer, Janessa Laskin, Roy S. Herbst, David H. Johnson, Herbert I. Hurwitz, David Miles, Regula Deurloo and Robert L. Coleman. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact